Useful For
Suggests clinical disorders or settings where the test may be helpful
Monitoring for appropriate therapeutic concentration of free phenytoin: free phenytoin level is the best indicator of adequate therapy in renal failure
Assessing compliance and toxicity
Method Name
A short description of the method used to perform the test
Membrane Separation/Kinetic Interaction Microparticles in Solution (KIMS)
NY State Available
Indicates the status of NY State approval and if the test is orderable for NY State clients.
Yes
Reporting Name
Lists a shorter or abbreviated version of the Published Name for a test
Phenytoin, Free, S
Aliases
Lists additional common names for a test, as an aid in searching
Dilantin Free, Serum
Free Dilantin
Free Dilantin, Serum
Free Phenytoin
Dilantin, Total and Free (ORDER PNTFT)
Specimen Type
Describes the specimen type validated for testing
Serum Red
Specimen Required
Defines the optimal specimen required to perform the test and the preferred volume to complete testing
Collection Container/Tube: Red top
Submission Container/Tube: Plastic vial
Specimen Volume: 2 mL
Collection Instructions: Centrifuge and aliquot serum into a plastic vial within 2 hours of collection.
Forms
Specimen Minimum Volume
Defines the amount of sample necessary to provide a clinically relevant result as determined by the testing laboratory. The minimum volume is sufficient for one attempt at testing.
Reject Due To
Identifies specimen types and conditions that may cause the specimen to be rejected
| Specimen Type |
Temperature |
Time |
Special Container |
|
Serum Red |
Refrigerated (preferred) |
7 days |
|
|
|
Frozen |
14 days |
|
|
|
Ambient |
7 days |
|
Useful For
Suggests clinical disorders or settings where the test may be helpful
Monitoring for appropriate therapeutic concentration of free phenytoin: free phenytoin level is the best indicator of adequate therapy in renal failure
Assessing compliance and toxicity
Phenytoin is the drug of choice to treat and prevent tonic-clonic and psychomotor seizures. If phenytoin alone will not prevent seizure activity, coadministration with phenobarbital is usually effective.
Phenytoin is highly protein-bound (90%), mostly to albumin. Ten percent of the phenytoin circulates in the free, unbound form. Free phenytoin is the active form of the drug, available to cross biologic membranes and bind to receptors. Increased free phenytoin produces an enhanced pharmacologic effect. At the same time, the free fraction is more available to the liver to be metabolized, so it is cleared more quickly.
Concurrent use of phenytoin and valproic acid (another frequently used antiepileptic) may result in altered valproic acid levels and/or altered phenytoin levels. Due to the complex situation involving displacement of protein-bound phenytoin and inhibition of phenytoin metabolism, as well as the potential for decreased valproic acid concentrations, patients should be monitored for both phenytoin toxicity and therapeutic efficacy. Free phenytoin levels should be measured to provide the most accurate assessment of phenytoin activity early in therapy. At steady-state, free phenytoin and free valproic acid concentrations should be normalized.
In renal failure, the opportunity for the free phenytoin fraction to be cleared is significantly reduced. The end result is that both the total and free concentration of phenytoin increase, with the free concentration increasing faster than the total. Dosage must be reduced to avoid toxicity. Accordingly, the free phenytoin level is the best indicator of adequate therapy in renal failure.
Toxicity is a constant possibility because of the manner in which phenytoin is metabolized. Small increases in dose can lead to very large increases in blood concentration, resulting in early signs of toxicity such as nystagmus, ataxia, and dysarthria. Severe toxicity is typified by tremor, hyperreflexia, lethargy, and coma.
Reference Values
Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
Therapeutic: 1.0-2.0 mcg/mL
Critical value: > or =2.5 mcg/mL
Interpretation
Provides information to assist in interpretation of the test results
Dose should be adjusted to achieve steady-state blood concentration of free phenytoin between 1.0 and 2.0 mcg/mL. The range for percent free phenytoin is 8% to 14%.
Severe toxicity occurs when the free phenytoin concentration is > or =2.5 mcg/mL. However, response and side effects will be individual.
Cautions
Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances
No significant cautionary statements
Clinical Reference
Recommendations for in-depth reading of a clinical nature
Richens A: Clinical pharmacokinetics of phenytoin. Clin Pharmacokinet 1979;4:153-169
Method Description
Describes how the test is performed and provides a method-specific reference
Fresh serum subjected to ultra-filtration to generate a protein-free filtrate, which is then analyzed for free phenytoin by the kinetic interaction of microparticles in a solution (KIMS). Phenytoin antibody is covalently coupled to microparticles and the drug derivative is linked to a macromolecule. The kinetic interaction of microparticles in solutions is induced by binding of drug-conjugate to the antibody on the microparticles and is inhibited by the presence of phenytoin in the sample. A competitive reaction takes place between the drug conjugate and phenytoin in the serum sample for binding to the phenytoin antibody on the microparticles. The resulting kinetic interaction of microparticles is indirectly proportional to the amount of drug present in the sample.(Package insert: Roche Phenytoin reagent, Roche Diagnostic Corp, Indianapolis, IN)
PDF Report
Indicates whether the report includes an additional document with charts, images or other enriched information
No
Monday through Sunday
Report Available
The interval of time (receipt of sample at Mayo Clinic Laboratories to results available) taking into account standard setup days and weekends. The first day is the time that it typically takes for a result to be available. The last day is the time it might take, accounting for any necessary repeated testing.
Same day/1 day
Rochester
Fees :
Several factors determine the fee charged to perform a test. Contact your U.S. or International Regional Manager for information about establishing a fee schedule or to learn more about resources to optimize test selection.
- Authorized users can sign in to Test Prices for detailed fee information.
- Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact Customer Service.
Test Classification
Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR) product.
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.
| Test Id |
Test Order Name |
Order LOINC Value
|
| PNYF |
Phenytoin, Free, S |
3969-3 |
| Result Id |
Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
| PNYF |
Phenytoin, Free, S |
3969-3 |